<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00566098</url>
  </required_header>
  <id_info>
    <org_study_id>J0770</org_study_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>NA_00012038</secondary_id>
    <nct_id>NCT00566098</nct_id>
  </id_info>
  <brief_title>Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma</brief_title>
  <official_title>Adoptive Immunotherapy Utilizing Activated Marrow Infiltrating Lymphocytes in the Autologous Transplant Setting in Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Activating white blood cells in the laboratory may help them kill more cancer
      cells when they are put back in the body. This may be an effective treatment for patients
      undergoing a stem cell transplant for multiple myeloma.

      PURPOSE: This phase I/II trial is studying the side effects of activated white blood cells
      and to see how well they work in treating patients who are undergoing a stem cell transplant
      for newly diagnosed stage II or stage III multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Evaluate the safety and response rate of activated marrow infiltrating lymphocytes
           (aMILs) in patients undergoing autologous peripheral blood stem cell transplantation for
           newly diagnosed, stage II-III multiple myeloma.

        -  Determine the overall in vitro fold-expansion and assess pre- and post-expansion for
           myeloma T-cell specificity in assessing the feasibility of generating aMILs from myeloma
           patients.

        -  Assess the toxicity of aMILs.

        -  Evaluate the effect of aMILs on hematopoietic engraftment, including neutrophil
           engraftment, platelet engraftment, and primary graft failure (if failure occurs).

        -  Evaluate response rates utilizing the Blade criteria, including the complete response
           (CR) rate, near complete response (nCR) rate, very good partial response (VGPR) rate,
           partial response (PR) rate, minimal response (MR) rate, and overall response rate (CR,
           VGPR, PR, MR).

      Secondary

        -  Evaluate T-cell reconstitution, including absolute lymphocyte counts, CD3+, CD4+, and
           CD8+ T-cell counts.

        -  Evaluate progression-free survival and overall survival.

        -  Evaluate anti-tumor immune response.

        -  Determine pneumococcal-specific vaccine responses.

        -  Determine delayed-type hypersensitivity (DTH) responses.

      OUTLINE: Patients undergo collection of marrow infiltrating lymphocytes (MILs)* either at
      diagnosis prior to the initiation of induction therapy or upon completion of induction
      therapy. The MILs bone marrow product undergo ex vivo activation and expansion of T cells for
      7-8 days to produce activated marrow infiltrating lymphocytes (aMILs). Patients then undergo
      stem cell mobilization and leukapheresis to collect the peripheral blood stem cells 12 days
      after mobilization. Patients receive melphalan IV over 20-30 minutes on days -2 and -1 and
      undergo a peripheral blood stem cell transplantation on day 0 as planned. Patients receive
      aMILs infusion on day 3. Patients receive pneumococcal polyvalent vaccine on day 21.

      NOTE: *Patients who have completed induction therapy receive pneumococcal polyvalent vaccine
      approximately 2 weeks prior to MILs collection; patients undergoing MILs collection prior to
      starting induction therapy do not receive a pre-transplantation vaccine.

      Blood and bone marrow samples are collected periodically for laboratory correlative studies.

      After completion of study treatment, patients are followed periodically for up to 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2007</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematopoietic Engraftment</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Days to absolute neutrophil count &gt; 500 cells per microliter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Percentage of participants with partial or complete response by Blad√© criteria. Partial response is defined as a &gt;= 50% decrease in serum paraprotein or 90% decrease in urinary light chains (for participants without measurable serum paraprotein). Complete response is defined as negative serum and urine immunofixation and a bone marrow aspirate with &lt; 5% plasma cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of MILs Generation as Assessed by Percentage of Participants With Successful MIL Generation</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Success rate of expanding MILs in vitro and obtaining a protocol-specified product.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T-cell Reconstitution as Determined by Absolute Lymphocyte Count (ALC)</measure>
    <time_frame>Days 14, 28, 60, 180, and 360</time_frame>
    <description>ALC counts trending over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Up to 129 months</time_frame>
    <description>Survival in months for participants who are alive (Overall Survival) and alive without disease progression (Progression-free survival). Disease progression is defined as a change from negative to positive on immunofixation or electrophoresis for participants previously in complete remission or a 25% increase in serum electrophoresis for participants not previously in complete remission. Partial response is defined as a &gt;= 50% decrease in serum paraprotein or 90% decrease in urinary light chains (for participants without measurable serum paraprotein). Complete response is defined as negative serum and urine immunofixation and a bone marrow aspirate with &lt; 5% plasma cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal-specific Vaccine Responses</measure>
    <time_frame>At time of bone marrow harvest, Day 60 post-transplant, Day 180 post-transplant, and Day 360 post-transplant</time_frame>
    <description>CRM-197 Prevnar-specific vaccine responses that measure the T-cell response of the vaccine quantified as %CD3+/CFSE-low/IFN-gamma+.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor Immune Responses</measure>
    <time_frame>At time of bone marrow harvest, Day 60 post-transplant, Day 180 post-transplant, and Day 360 post-transplant</time_frame>
    <description>Myeloma lysate response that measures the T-cell response quantified as %CD3+/CFSE-low/IFN-gamma+.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>ASCT+MILs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous stem cell transplant with a conditioning regimen of melphalan 100 mg/m^2 on each of Days -2 and -1. Infusion of activated marrow infiltrating lymphocytes (MILs) on Day 3. PCV13 vaccine will be given before and/or after Day 0 depending on when participants are enrolled.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MILs</intervention_name>
    <arm_group_label>ASCT+MILs</arm_group_label>
    <other_name>Marrow infiltrating lymphocytes</other_name>
    <other_name>Activated marrow infiltrating lymphocytes</other_name>
    <other_name>aMILs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <arm_group_label>ASCT+MILs</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PCV13</intervention_name>
    <arm_group_label>ASCT+MILs</arm_group_label>
    <other_name>Prevnar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of multiple myeloma

               -  Newly diagnosed disease

               -  Durie-Salmon stage II or III disease

          -  Measurable disease, defined by any of the following:

               -  Measurable serum and/or urine M-protein levels documented and available prior to
                  induction therapy

               -  Positive serum free light chain assay

          -  Must have completed a minimum of 3 courses of myeloma specific therapy

          -  Candidate for autologous stem cell transplantation

          -  Patients who have achieved a complete remission at the time of bone marrow harvest for
             marrow infiltrating lymphocytes (MILs) expansion are not eligible

          -  No evidence of spinal cord compression

          -  Diagnosis of the following cancers are not allowed:

               -  POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly,
                  endocrinopathy, monoclonal protein and skin changes)

               -  Non-secretory myeloma (no measurable protein on serum free light chain assay)

               -  Plasma cell leukemia

          -  No amyloidosis

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy ‚â• 6 months

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and up to day 180

          -  Corrected serum calcium &lt; 11 mg/dL and no evidence of symptomatic hypercalcemia

          -  Total bilirubin ‚â§ 2.0 times upper limit of normal (ULN)

          -  ALT ‚â§ 2.0 times ULN

          -  Serum creatinine &lt; 2.0 mg/dL

          -  No history of other malignancy within the past 5 years, except adequately treated
             basal cell or squamous cell skin cancer

          -  No history of autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis,
             systemic lupus erythematosus) requiring systemic treatment

               -  Hypothyroidism without evidence of Graves' disease or Hashimoto thyroiditis is
                  allowed

          -  No infection requiring treatment with antibiotics, antifungal, or antiviral agents
             within the past 7 days

          -  No HIV infection

          -  No major organ system dysfunction including, but not limited to, the following:

               -  New York Heart Association class III or IV congestive heart failure

               -  Pulmonary disease requiring the use of inhaled steroids or bronchodilators

               -  Renal, hepatic, gastrointestinal, neurologic, or psychiatric dysfunction that
                  would impair ability to participate in the study

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior hematopoietic stem cell transplantation

          -  At least 3 weeks since prior corticosteroids (i.e., glucocorticoids)

          -  At least 3 weeks since prior myeloma-specific therapy

          -  At least 4 weeks since participation in any clinical trial that involved an
             investigational drug or device

          -  No concurrent therapy with any of the following:

               -  Corticosteroids (e.g., hydrocortisone, prednisone, prednisolone, dexamethasone
                  [Decadron])

                    -  Inhaled steroids used for treatment of allergic rhinitis or pulmonary
                       disease allowed

               -  Thalidomide

               -  Interferon

               -  Growth factors, interleukins, or other cytokines (except filgrastim [G-CSF] as
                  outlined in the protocol, or erythropoietin)

               -  Cytotoxic chemotherapy agents (except cyclophosphamide for stem cell mobilization
                  and high-dose melphalan)

               -  Immunosuppressive drugs

               -  Experimental therapies

               -  Radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan Borrello, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Noonan KA, Huff CA, Davis J, Lemas MV, Fiorino S, Bitzan J, Ferguson A, Emerling A, Luznik L, Matsui W, Powell J, Fuchs E, Rosner GL, Epstein C, Rudraraju L, Ambinder RF, Jones RJ, Pardoll D, Borrello I. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Sci Transl Med. 2015 May 20;7(288):288ra78. doi: 10.1126/scitranslmed.aaa7014.</citation>
    <PMID>25995224</PMID>
  </results_reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 30, 2007</study_first_submitted>
  <study_first_submitted_qc>November 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2007</study_first_posted>
  <results_first_submitted>September 14, 2018</results_first_submitted>
  <results_first_submitted_qc>November 29, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 19, 2018</results_first_posted>
  <last_update_submitted>November 29, 2018</last_update_submitted>
  <last_update_submitted_qc>November 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There was one screen failure.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MILs in Patients Undergoing an Autologous Peripheral SCT</title>
          <description>therapeutic autologous lymphocytes
therapeutic tumor infiltrating lymphocytes
melphalan
autologous hematopoietic stem cell transplantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Collection of MILs</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relapsed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Generation of MILs Product</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Relapsed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Administration of ASCT+MILs</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MILs in Patients Undergoing an Autologous Peripheral SCT</title>
          <description>therapeutic autologous lymphocytes
therapeutic tumor infiltrating lymphocytes
melphalan
autologous hematopoietic stem cell transplantation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="30" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hematopoietic Engraftment</title>
        <description>Days to absolute neutrophil count &gt; 500 cells per microliter.</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MILs in Patients Undergoing an Autologous Peripheral SCT</title>
            <description>therapeutic autologous lymphocytes
therapeutic tumor infiltrating lymphocytes
melphalan
autologous hematopoietic stem cell transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Hematopoietic Engraftment</title>
          <description>Days to absolute neutrophil count &gt; 500 cells per microliter.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" lower_limit="12" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease Response</title>
        <description>Percentage of participants with partial or complete response by Blad√© criteria. Partial response is defined as a &gt;= 50% decrease in serum paraprotein or 90% decrease in urinary light chains (for participants without measurable serum paraprotein). Complete response is defined as negative serum and urine immunofixation and a bone marrow aspirate with &lt; 5% plasma cells.</description>
        <time_frame>Up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MILs in Patients Undergoing an Autologous Peripheral SCT</title>
            <description>therapeutic autologous lymphocytes
therapeutic tumor infiltrating lymphocytes
melphalan
autologous hematopoietic stem cell transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Response</title>
          <description>Percentage of participants with partial or complete response by Blad√© criteria. Partial response is defined as a &gt;= 50% decrease in serum paraprotein or 90% decrease in urinary light chains (for participants without measurable serum paraprotein). Complete response is defined as negative serum and urine immunofixation and a bone marrow aspirate with &lt; 5% plasma cells.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Feasibility of MILs Generation as Assessed by Percentage of Participants With Successful MIL Generation</title>
        <description>Success rate of expanding MILs in vitro and obtaining a protocol-specified product.</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MILs in Patients Undergoing an Autologous Peripheral SCT</title>
            <description>therapeutic autologous lymphocytes
therapeutic tumor infiltrating lymphocytes
melphalan
autologous hematopoietic stem cell transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility of MILs Generation as Assessed by Percentage of Participants With Successful MIL Generation</title>
          <description>Success rate of expanding MILs in vitro and obtaining a protocol-specified product.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T-cell Reconstitution as Determined by Absolute Lymphocyte Count (ALC)</title>
        <description>ALC counts trending over time.</description>
        <time_frame>Days 14, 28, 60, 180, and 360</time_frame>
        <population>Data was not collected on one participant at the Day 28 and 180 timepoints, and data was not collected for eight participants at the Day 360 timepoint. Data was not collected on CD3+/CD4+/CD8+ cells for all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>MILs in Patients Undergoing an Autologous Peripheral SCT</title>
            <description>therapeutic autologous lymphocytes
therapeutic tumor infiltrating lymphocytes
melphalan
autologous hematopoietic stem cell transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>T-cell Reconstitution as Determined by Absolute Lymphocyte Count (ALC)</title>
          <description>ALC counts trending over time.</description>
          <population>Data was not collected on one participant at the Day 28 and 180 timepoints, and data was not collected for eight participants at the Day 360 timepoint. Data was not collected on CD3+/CD4+/CD8+ cells for all participants.</population>
          <units>cells per microliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="756" lower_limit="105" upper_limit="2397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1768" lower_limit="349" upper_limit="3760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1700" lower_limit="530" upper_limit="3500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1430" lower_limit="650" upper_limit="2340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 360</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1660" lower_limit="690" upper_limit="2420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival</title>
        <description>Survival in months for participants who are alive (Overall Survival) and alive without disease progression (Progression-free survival). Disease progression is defined as a change from negative to positive on immunofixation or electrophoresis for participants previously in complete remission or a 25% increase in serum electrophoresis for participants not previously in complete remission. Partial response is defined as a &gt;= 50% decrease in serum paraprotein or 90% decrease in urinary light chains (for participants without measurable serum paraprotein). Complete response is defined as negative serum and urine immunofixation and a bone marrow aspirate with &lt; 5% plasma cells.</description>
        <time_frame>Up to 129 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MILs in Patients Undergoing an Autologous Peripheral SCT</title>
            <description>therapeutic autologous lymphocytes</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>Survival in months for participants who are alive (Overall Survival) and alive without disease progression (Progression-free survival). Disease progression is defined as a change from negative to positive on immunofixation or electrophoresis for participants previously in complete remission or a 25% increase in serum electrophoresis for participants not previously in complete remission. Partial response is defined as a &gt;= 50% decrease in serum paraprotein or 90% decrease in urinary light chains (for participants without measurable serum paraprotein). Complete response is defined as negative serum and urine immunofixation and a bone marrow aspirate with &lt; 5% plasma cells.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.1" lower_limit="39.9" upper_limit="128.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression-free survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" lower_limit="8.8" upper_limit="69.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumococcal-specific Vaccine Responses</title>
        <description>CRM-197 Prevnar-specific vaccine responses that measure the T-cell response of the vaccine quantified as %CD3+/CFSE-low/IFN-gamma+.</description>
        <time_frame>At time of bone marrow harvest, Day 60 post-transplant, Day 180 post-transplant, and Day 360 post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MILs in Patients Undergoing an Autologous Peripheral SCT</title>
            <description>therapeutic autologous lymphocytes
therapeutic tumor infiltrating lymphocytes
melphalan
autologous hematopoietic stem cell transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal-specific Vaccine Responses</title>
          <description>CRM-197 Prevnar-specific vaccine responses that measure the T-cell response of the vaccine quantified as %CD3+/CFSE-low/IFN-gamma+.</description>
          <units>%CD3+/CFSE-low/IFN-gamma+</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At time of bone marrow harvest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" lower_limit="0.12" upper_limit="47.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60 post-transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" lower_limit="0" upper_limit="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180 post-transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4" lower_limit="7" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 360 post-transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" lower_limit="0" upper_limit="49.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-tumor Immune Responses</title>
        <description>Myeloma lysate response that measures the T-cell response quantified as %CD3+/CFSE-low/IFN-gamma+.</description>
        <time_frame>At time of bone marrow harvest, Day 60 post-transplant, Day 180 post-transplant, and Day 360 post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MILs in Patients Undergoing an Autologous Peripheral SCT</title>
            <description>therapeutic autologous lymphocytes
therapeutic tumor infiltrating lymphocytes
melphalan
autologous hematopoietic stem cell transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-tumor Immune Responses</title>
          <description>Myeloma lysate response that measures the T-cell response quantified as %CD3+/CFSE-low/IFN-gamma+.</description>
          <units>%CD3+/CFSE-low/IFN-gamma+</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At time of bone marrow harvest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" lower_limit="0" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60 post-transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" lower_limit="0" upper_limit="44.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180 post-transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" lower_limit="0.6" upper_limit="50.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 360 post-transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" lower_limit="0" upper_limit="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Day 360</time_frame>
      <desc>Per protocol, only adverse events (AEs) that were attributed to the study product (MILs) were collected and reported. AEs were collected daily through the date of engraftment, weekly through Day 28, and then at Days 60, 180, and 360.</desc>
      <group_list>
        <group group_id="E1">
          <title>ASCT+MILs</title>
          <description>Autologous stem cell transplant with a conditioning regimen of melphalan 100 mg/m^2 on each of Days -2 and -1. Infusion of activated marrow infiltrating lymphocytes (MILs) on Day 3. PCV13 vaccine will be given before and/or after Day 0 depending on when participants are enrolled.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenic fever</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - abdomen</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pain - calf</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="22" subjects_affected="12" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ivan Borrello, MD</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>4109554967</phone>
      <email>iborrell@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

